$AIMDW News
Last published 4y ago
- 4y agoAIMDAIMDWAinos Announces Positive Results from Additional Preclinical Study of Its Low-dose Oral Interferon Formulation Against New Variant Virus - OmicronACCESS NewswireVELDONA® formulation showed significant stabilization of physical condition and complete recovery from lung inflammation throughout the course of treatment period. By upregulation of immunomodulatory, Ainos' VELDONA® formulation demonstrates efficacy
- 4y agoAIMDAIMDWAinos Submits Investigational New Drug Application to the U.S. FDA to Conduct Phase 2 Trial of its VELDONA Low-dose Oral Interferon Formulation Against Mild COVID-19 SymptomsACCESS NewswireSAN DIEGO, CA / ACCESSWIRE / August 24, 2022 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-dr
- 4y agoAIMDAIMDWAinos Announces Master Services Agreement with Swiss Pharmaceutical, Ltd. for Drug Testing, Manufacturing, and Packaging for its VELDONA Product CandidatesACCESS NewswireSAN DIEGO, CA / ACCESSWIRE / August 17, 2022 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-dr
- 4y agoAIMDAIMDWAinos Reports Second Quarter 2022 Financial ResultsACCESS NewswireSAN DIEGO, CA / ACCESSWIRE / August 15, 2022 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-dr
- 4y agoAIMDAIMDWAinos Announces Closing of $3.3 Million Public Offering, Uplisting to NASDAQ, and Reverse Stock SplitACCESS NewswireSAN DIEGO, CA / ACCESSWIRE / August 11, 2022 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-dr